AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 21 min read$CVKD

Pham Quang X sold $22K of CVKD

Pham Quang X (Chairman and CEO) sold 7,400 shares of Cadrenal Therapeutics, Inc. (CVKD) at $3.03 on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Pham Quang X
Published Jul 2, 2026, 1:52 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CVKD
Neutral
medium confidence
Mentioned
$CVKD
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CVKDNeutralLow
01

Why it matters

The disclosure confirms an insider open-market sale (7,400 shares) at a stated price, but provides no new business or financial guidance in the text.

02

Market read

Primarily a sentiment/positioning datapoint; likely limited trading impact absent additional catalysts.

03

What to watch

Traders may overreact to insider sales; without concurrent fundamentals (earnings, trial, financing, or regulatory updates), the signal is typically weak.

Relevance 2/10Novelty 5/10Timing: new SEC Form 4 filed July 1 (covers sale dated June 29)

Background

The article is an SEC Form 4 insider transaction for Cadrenal Therapeutics, Inc. (CVKD).

Company-level read

Ticker impact

$CVKDNeutralMedium confidence
Context

SEC Form 4 shows CVKD chairman/CEO Pham Quang X sold 7,400 shares on 2026-06-29 at $3.03 via a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely muted unless accompanied by other company-specific news.

Evidence & confidence

The filing is a disclosed open-market sale under a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change in the text.

Market effects

Sector

No sector read-through; this is company-specific insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled diversification rather than bearish expectations.

Key entities

  • issuer
    Cadrenal Therapeutics, Inc.

    Company whose insider transaction is disclosed on SEC Form 4.

  • insider
    Pham Quang X

    Chairman and CEO and 10% owner who sold shares under a pre-arranged 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CVKD insider trading history →

Related articles

AUG 13
$CVKDMed

Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the…

Cadrenal Therapeutics, Inc. (CVKD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio org

SEC EDGAR 8-K6 min
JUL 13
$CVKDMedAI 8/10

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress

Cadrenal Therapeutics (Nasdaq: CVKD) said Phase 2 late-breaking data for its 12-LOX inhibitor CAD-1005 were presented at ISTH 2026. In HIT, CAD-1005 showed an absolute reduction of more than 25% in new or worsening thrombotic events vs placebo (50% vs >75%) and no CAD-1005-attributable serious adverse events or deaths. Company cites $2B peak annual revenue potential.

manilatimes.net4 min
JUN 22
$CVKDMed

Cadrenal Advances Tecarfarin Toward FDA Rare Pediatric Disease Filing In Kawasaki Disease

Cadrenal Therapeutics said it plans to file for FDA Rare Pediatric Disease designation for tecarfarin in children with Kawasaki disease who develop coronary artery aneurysms. The company says tecarfarin is designed to provide more stable anticoagulation than warfarin. If approved, Cadrenal could receive a Priority Review Voucher, which it notes has sold for $180M–$205M.

rttnews.com5 min
SEP 29
$COURMedAI 8/10

Pale Fire Capital SE (Senkypl Dusan, Barta Jan) purchased $11.4M of COUR (indirect holdings)

Pale Fire Capital SE purchased 2,332,742 indirectly-held shares of Coursera, Inc. (COUR) at an average of $4.87 ($4.61–$5.06, $11.36M total) across 2 trades over 2026-09-25 to 2026-09-29. Filed jointly with Pale Fire Capital SICAV a.s. (10% owner), Pale Fire Capital investicni spolecnost a.s. (10% owner), Senkypl Dusan (10% owner) and Barta Jan (10% owner).

SEC EDGAR1 min